Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20791554 | 0.81 | MAPT (0.67) | AKR1C3MEN1KMT2AMAPTNPC1 | |
| SCHEMBL18977620 | 0.80 | CYP2C9 (0.55) | MEN1KMT2ACYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL2557643 | 0.79 | PKM (0.58) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL3350798 | 0.77 | MAPT (0.72) | MEN1KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL21510169 | 0.77 | PKM (0.59) | MEN1KMT2ACYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL28356029 | 0.77 | MAPT (0.67) | AKR1C3MEN1KMT2AMAPTNPC1 | |
| SCHEMBL15765139 | 0.77 | MMP2 (0.49) | NAMPTALDH1A1LMNA | |
| SCHEMBL1832051 | 0.76 | USP2 (0.71) | MEN1KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL26314073 | 0.76 | USP2 (0.71) | MEN1KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL18547806 | 0.75 | MEN1 (0.57) | AKR1C3MEN1KMT2AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257191-A2 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257191-A2 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220267306-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-08-25 | — | — | US | disclosed |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-07-05 | — | — | US | disclosed |
| CN-114685453-A | Heterocyclic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-109476637-B | Heterocyclic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20190322645-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190322645-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3472149-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222915-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322645-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, HTRA2 | AKR1C3 239/4885MEN1 4261/4885KMT2A 2140/4885 |
| US-20220267306-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, HTRA2 | AKR1C3 216/4885MEN1 4307/4885KMT2A 2190/4885 |
| US-11377439-B2 | Heterocyclic prolinamide derivatives | HTRA1, ALDH1A2, HTRA2 | AKR1C3 239/4885MEN1 4261/4885KMT2A 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.